Came across this article discussing recent advancements in circulating tumor DNA (ctDNA) technology for detecting minimal residual disease (MRD) post-surgery/treatment. Seems like sensitivity is improving, potentially offering a better way to stratify risk and guide adjuvant therapy decisions. Thought folks here, especially those using or considering Signatera/other assays, might find it interesting. Article
Interesting tech, but what’s the insurance coverage like? That’s always my first question. Cutting edge is great if you can access it.
Coverage is getting better, Daniel, but can still be a fight depending on your insurance plan and stage/indication. My major cancer center advocated strongly for it. Definitely something to discuss upfront.